On August 2, 2018, Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that it filed for an emergency asset freeze and other emergency relief.  The company also announced that it has agreed to pay over $1.5 million to settle a pending litigation action by the U.S. District Court for the Southern District of New York.  The SEC's complaint alleges that Acorda violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The SEC's complaint charges Acorda with violating Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and seeks permanent injunctions, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties.  The SEC's investigation, which is continuing, has been conducted by Kelechi Chikere, Carmen Augustine, and Gregory Chico of the SEC's Boston Regional Office.  The litigation will be led by Mr. Chikere and Ms. Augustine.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.